Hermann Christopher D, Wilson David S, Lawrence Kelsey A, Ning Xinghai, Olivares-Navarrete Rene, Williams Joseph K, Guldberg Robert E, Murthy Niren, Schwartz Zvi, Boyan Barbara D
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology Atlanta, GA, USA; Emory University School of Medicine, Atlanta, GA, USA.
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology Atlanta, GA, USA.
Biomaterials. 2014 Dec;35(36):9698-708. doi: 10.1016/j.biomaterials.2014.07.065. Epub 2014 Aug 28.
Craniosynostosis is the premature fusion of cranial sutures, which can result in progressive cranial deformations, increased intracranial pressure, and restricted brain growth. Most cases of craniosynostosis require surgical reconstruction of the cranial vault with the goal of increasing the intracranial volume and correcting the craniofacial deformities. However, patients often experience rapid post-operative bone regrowth, known as re-synostosis, which necessitates additional surgical intervention. Bone morphogenetic protein (BMP) inhibitors have tremendous potential to treat re-synostosis, but the realization of a clinically viable inhibitor-based therapeutic requires the development of a delivery vehicle that can localize the release to the site of administration. Here, we present an in situ rapidly crosslinking injectable hydrogel that has the properties necessary to encapsulate co-administered proteins and demonstrate that the delivery of rmGremlin1 via our hydrogel system delays bone regrowth in a weanling mouse model of re-synostosis. Our hydrogel is composed of two mutually reactive poly(ethylene glycol) macromolecules, which when mixed crosslink via a bio-orthogonal Cu free click reaction. Hydrogels containing Gremlin caused a dose dependent inhibition of bone regrowth. In addition to craniofacial applications, our injectable click hydrogel has the potential to provide customizable protein, small molecule, and cell delivery to any site accessible via needle or catheter.
颅缝早闭是颅缝的过早融合,可导致渐进性颅骨畸形、颅内压升高和脑生长受限。大多数颅缝早闭病例需要进行颅盖骨手术重建,目的是增加颅内体积并纠正颅面畸形。然而,患者术后常出现快速的骨再生,即再次骨缝早闭,这需要额外的手术干预。骨形态发生蛋白(BMP)抑制剂在治疗再次骨缝早闭方面具有巨大潜力,但要实现基于抑制剂的临床可行治疗方法,需要开发一种能够将释放定位到给药部位的递送载体。在此,我们展示了一种原位快速交联可注射水凝胶,它具有封装共同给药蛋白质所需的特性,并证明通过我们的水凝胶系统递送重组蛋白Gremlin1可延缓断奶小鼠再次骨缝早闭模型中的骨再生。我们的水凝胶由两个相互反应的聚乙二醇大分子组成,混合时通过无铜生物正交点击反应交联。含有Gremlin的水凝胶对骨再生产生剂量依赖性抑制。除了颅面应用外,我们的可注射点击水凝胶有可能为任何可通过针头或导管到达的部位提供可定制的蛋白质、小分子和细胞递送。